Neurokinin-1 receptor: Functional significance in the immune system in reference to selected infections and inflammation

Annals of the New York Academy of Sciences

Volumn 1217, Issue 1, 2011, Pages 83-95

  Douglas, Steven D ^a   Leeman, Susan E ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immunology; Neurokinin 1 receptor; Substance P

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOPROTEIN; NEUROKININ 1 RECEPTOR; SUBSTANCE P;

ARTICLE; BACTERIAL INFECTION; HUMAN; IMMUNE SYSTEM; MYCOSIS; NONHUMAN; PARASITOSIS; PROTEIN FUNCTION; RECEPTOR BINDING; VIRUS INFECTION;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 79251535010     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05826.x     Document Type: Article

References (128)

1. Pascual, D.W. 2004. The role of tachykinins on bacterial infections. Front Biosci. 9: 3209-3217.
2. Bremer, A.A. & S.E. Leeman 2010. Substance P. In Encyclopedia of Life Sciences (ELS). John Wiley & Sons, Ltd. Chichester, DOI.
3. Lai, J.P. et al 1998. Identification of a delta isoform of preprotachykinin mRNA in human mononuclear phagocytes and lymphocytes. J. Neuroimmunol. 91: 121-128.
4. Page, N.M. 2006. Characterization of the gene structures, precursor processing and pharmacology of the endokinin peptides. Vascul. Pharmacol. 45: 200-208.
5. Severini, C. et al 2002. The tachykinin peptide family. Pharmacol. Rev. 54: 285-322.
6. Pennefather, J.N. et al 2004. Tachykinins and tachykinin receptors: a growing family. Life Sci. 74: 1445-1463.
7. Patacchini, R. et al 2004. Newly discovered tachykinins raise new questions about their peripheral roles and the tachykinin nomenclature. Trends Pharmacol. Sci. 25: 1-3.
8. Baby, S. et al 1999. Substance P antagonists: the next breakthrough in treating depression? J. Clin. Pharm. Therapeut. 24: 461-469.
9. Nelson, D.A. & K.L. Bost 2004. Non-neuronal mammalian tachykinin expression. Front. Biosci. 9: 2166-2176.
10. Nelson, D.A., I. Marriott & K.L. Bost 2004. Expression of hemokinin 1 mRNA by murine dendritic cells. J. Neuroimmunol. 155: 94-102.
11. Metwali, A. et al 2004. Cutting edge: hemokinin has substance p-like function and expression in inflammation. J. Immunol. 172: 6528-6532.
12. von Euler, U.S. & J.H. Gaddum 1932. An unidentified depressor substance in certain tissue extracts. J. Physiol. (Lond). 72: 577-583.
13. Chang, M.M. & S.E. Leeman 1970. Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P. J. Biol. Chem. 245: 4784-4790.
14. Chang, M.M., S.E. Leeman & H.D. Niall 1971. Amino-acid sequence of substance P. Nat.-New Biol. 232: 86-87.
15. Vinet-Oliphant, H. et al 2010. Neurokinin-1 receptor (NK1-R) expression in the brains of SIV-infected Rhesus macaques: implications for substance P in NK1-R immune cell trafficking into the CNS. Am. J. Pathol. 177: 1286-1297.
16. Bost, K.L. 2004. Tachykinin-mediated modulation of the immune response. Front. Biosci. 9: 3331-3332.
17. Ho, W.Z. et al 1997. Human monocytes and macrophages express substance P and neurokinin-1 receptor. J. Immunol. 159: 5654-5660.
18. Satake, H. & T. Kawada 2006. Overview of the primary structure, tissue-distribution, and functions of tachykinins and their receptors. Curr. Drug Targets. 7: 963-974.
19. Greco, S.J. et al 2004. Tachykinins in the emerging immune system: relevance to bone marrow homeostasis and maintenance of hematopoietic stem cells. Front. Biosci. 9: 1782-1793.
20. Maggi, C.A. 1997. The effects of tachykinins on inflammatory and immune cells. Regul. Pept. 70: 75-90.
21. Ho, W.Z. & S.D. Douglas 2004. Substance P and neurokinin-1 receptor modulation of HIV. J. Neuroimmunol. 157: 48-55.
22. Lai, J.P. et al 2002. A non-peptide substance P antagonist down-regulates SP mRNA expression in human mononuclear phagocytes. J. Neuroimmunol. 128: 101-108.
23. Caberlotto, L. et al 2003. Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain. Eur. J. Neurosci. 17: 1736-1746.
24. Lai, J.P. et al 2001. Substance P antagonist (CP-96, 345) inhibits HIV-1 replication in human mononuclear phagocytes. Proc. Natl. Acad. Sci. USA 98: 3970-3975.
25. Mantyh, C.R. et al 1988. Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles, venules, lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn disease. Proc. Natl. Acad. Sci. USA 85: 3235-3239.
26. Mantyh, P.W. et al 1989. Substance P receptor binding sites are expressed by glia in vivo after neuronal injury. Proc. Natl. Acad. Sci. USA 86: 5193-5197.
27. Kennedy, K.J. et al 1998. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1. J. Neuroimmunol. 92: 98-108.
28. Kennedy, P.G. et al 2003. Clinical and neuroinflammatory responses to meningoencephalitis in substance P receptor knockout mice. Brain 126: 1683-1690.
29. Kennedy, P.G. et al 1997. A substance P antagonist, RP-67, 580, ameliorates a mouse meningoencephalitic response to Trypanosoma brucei brucei. Proc. Natl. Acad. Sci. USA 94: 4167-4170.
30. Berrettini, W.H. et al 1985. CSF substance P immunoreactivity in affective disorders. Biol. Psychiatry 20: 965-970.
31. Rupniak, N.M. 2003. Animal models of depression challenges from a drug development perspective. Behav. Pharmacol. 14: 385-390.
32. Rupniak, N.M. 2002. Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. Curr. Opin. Investig. Drugs. 3: 257-261.
33. Rupniak, N.M. & M.S. Kramer 1999. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol. Sci. 20: 485-490.
34. Goodman, A. 2008. Neurobiology of addiction. An integrative review. Biochem. Pharmacol. 75: 266-322.
35. O'Connor, T.M. et al 2004. The role of substance P in inflammatory disease. J. Cell. Physiol. 201: 167-180.
36. Ebner, K. & N. Singewald 2006. The role of substance P in stress and anxiety responses. Amino Acids 31: 251-272.
37. Ho, W.Z. et al 2002. HIV enhances substance P expression in human immune cells. FASEB J. 16: 616-618.
38. Lai, J.P., S.D. Douglas & W.Z. Ho 1998. Human lymphocytes express substance P and its receptor. J. Neuroimmunol. 86: 80-86.
39. Lai, J.P. et al 2000. Detection of substance P and its receptor in human fetal microglia. Neuroscience 101: 1137-1144.
40. Li, Y., S.D. Douglas & W. Ho 2000. Human stem cells express substance P gene and its receptor. J. Hematother. Stem Cell Res. 9: 445-452.
41. Li, Y. et al 2003. Human neuronal cells (NT2-N) express functional substance P and neurokinin-1 receptor coupled to MIP-1 beta expression. J. Neurosci. Res. 71: 559-566.
42. Goode, T. et al 2000. Differential expression of neurokinin-1 receptor by human mucosal and peripheral lymphoid cells. Clin. Diag. Lab. Immunol. 7: 371-376.
43. Manak, M. et al 2008. Anti-HIV activity of aprepitant and synergistic interactions with other antiretrovirals. In 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA.
44. Wang, X. et al 2004. A non-peptide substance P antagonist (CP-96, 345) inhibits morphine-induced NF-kappaB promoter activation in human NT2-N neurons. J. Neurosci. Res. 75: 544-553.
45. Lai, J.-P. et al 2008. Detection of full-length and truncated neurokinin-1 receptor mRNA expression in human brain regions. J. Neurosci. Methods 168: 127-133.
46. Douglas, S.D., K.G. Lynch & J.P. Lai 2008. Neurokinin-1 receptor mRNA expression differences in brains of HIV-infected individuals. J. Neurol. Sci. 272: 174-177.
47. Hartung, H.P., K. Wolters & K.V. Toyka 1986. Substance P binding properties and studies on cellular responses in guinea pig macrophages. J. Immunol. 136: 3856-3863.
48. Michaels, L.A. et al 1998. Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis. Blood 92: 3148-3151.
49. Douglas, S.D. et al 2001. Elevated substance P levels in HIV-infected men. AIDS 15: 2043-2045.
50. Ho, W.Z. et al 1996. Substance P modulates human immunodeficiency virus replication in human peripheral blood monocyte-derived macrophages. AIDS Res. Hum. Retroviruses 12: 195-198.
51. Douglas, S.D. et al 2008. Elevated substance P levels in HIV-infected women in comparison to HIV-negative women. AIDS Res. Hum. Retroviruses 24: 375-378.
52. Wang, X. et al 2007. Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro. J. Neuroimmune Pharmacol. 2: 42-48.
53. Wang, X. et al 2008. Neurokinin-1 receptor antagonist (Aprepitant) suppresses HIV-1 infection of microglia/macrophages. J. Neuroimmune Pharmacol. 3: 257-264.
54. Almeida, T.A. et al 2004. Tachykinins and tachykinin receptors: structure and activity relationships. Curr. Med. Chem. 11: 2045-2081.
55. Gerard, N.P. et al 1990. The human neurokinin A (substance K) receptor. Molecular cloning of the gene, chromosome localization, and isolation of cDNA from tracheal and gastric tissues. J. Biol. Chem. 265: 20455-20462.
56. Gerard, N.P. et al 1991. Human substance P receptor (NK-1): organization of the gene, chromosome localization, and functional expression of cDNA clones. Biochemistry (Mosc) 30: 10640-10646.
57. Krause, J.E. et al 1993. Structure, expression and second messenger-mediated regulation of the human and rat substance P receptors and their genes. Regul. Pept. 46: 59-66.
58. Maggi, C.A. 1995. The mammalian tachykinin receptors. Gen. Pharmacol. 26: 911-944.
59. Maggi, C.A. & T.W. Schwartz 1997. The dual nature of the tachykinin NK1 receptor. Trends Pharmacol. Sci. 18: 351-355.
60. Masu, Y. et al 1987. cDNA cloning of bovine substance-K receptor through oocyte expression system. Nature 329: 836-838.
61. Nakanishi, S. et al 1990. Molecular characterization of mammalian tachykinin receptors and a possible epithelial potassium channel. Recent Prog. Horm. Res. 46: 59-83; discussion 83-54.
62. Shigemoto, R. et al 1990. Cloning and expression of a rat neuromedin K receptor cDNA. J. Biol. Chem. 265: 623-628.
63. Takahashi, K. et al 1992. The primary structure and gene organization of human substance P and neuromedin K receptors. Eur. J. Biochem. 204: 1025-1033.
64. Torrens, Y. et al 1989. Tachykinin receptors of the NK1 type (substance P) coupled positively to phospholipase C on cortical astrocytes from the newborn mouse in primary culture. J. Neurochem. 52: 1913-1918.
65. Yokota, Y. et al 1989. Molecular characterization of a functional cDNA for rat substance P receptor. J. Biol. Chem. 264: 17649-17652.
66. Blount, P. & J.E. Krause 1993. Functional nonequivalence of structurally homologous domains of neurokinin-1 and neurokinin-2 type tachykinin receptors. J. Biol. Chem. 268: 16388-16395.
67. Holst, B. et al 2001. Two active molecular phenotypes of the tachykinin NK1 receptor revealed by G-protein fusions and mutagenesis. J. Biol. Chem. 276: 19793-19799.
68. Labrou, N.E. et al 2001. Interaction of Met297 in the seventh transmembrane segment of the tachykinin NK2 receptor with neurokinin A. J. Biol. Chem. 276: 37944-37949.
69. Lecat, S. et al 2002. Mutations in the extracellular amino-terminal domain of the NK2 neurokinin receptor abolish cAMP signaling but preserve intracellular calcium responses. J. Biol. Chem. 277: 42034-42048.
70. Nakajima, Y. et al 1992. Direct linkage of three tachykinin receptors to stimulation of both phosphatidylinositol hydrolysis and cyclic AMP cascades in transfected Chinese hamster ovary cells. J. Biol. Chem. 267: 2437-2442.
71. Palanche, T. et al 2001. The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J. Biol. Chem. 276: 34853-34861.
72. Hunter, J.C., M. Goedert & R.D. Pinnock 1985. Mammalian tachykinin-induced hydrolysis of inositol phospholipids in rat brain slices. Biochem. Biophys. Res. Commun. 127: 616-622.
73. Ma, H.T. et al 2001. Assessment of the role of the inositol 1, 4, 5-trisphosphate receptor in the activation of transient receptor potential channels and store-operated Ca2+ entry channels. J. Biol. Chem. 276: 18888-18896.
74. Randolph, G.P. et al 2004. Identification of single-nucleotide polymorphisms of the human neurokinin 1 receptor gene and pharmacological characterization of a Y192H variant. Pharmacogenomics J. 4: 394-402.
75. Fong, T.M. et al 1992. Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor. Mol. Pharmacol. 41: 24-30.
76. Lai, J.P. et al 2006. Full-length and truncated neurokinin-1 receptor expression and function during monocyte/macrophage differentiation. Proc. Natl. Acad. Sci. USA 103: 7771-7776.
77. Lai, J.P. et al 2008. Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor. Proc. Natl. Acad. Sci. USA 105: 12605-12610.
78. Baker, S.J., J.L. Morris & I.L. Gibbins 2003. Cloning of a C-terminally truncated NK-1 receptor from guinea-pig nervous system. Brain Res. Mol. Brain Res. 111: 136-147.
79. Bohm, S.K. et al 1997. Identification of potential tyrosine-containing endocytic motifs in the carboxyl-tail and seventh transmembrane domain of the neurokinin 1 receptor. J. Biol. Chem. 272: 2363-2372.
80. Li, H. et al 1997. A substance P (neurokinin-1) receptor mutant carboxylterminally truncated to resemble a naturally occurring receptor isoform displays enhanced responsiveness and resistance to desensitization. Proc. Natl. Acad. Sci. USA 94: 9475-9480.
81. DeFea, K.A. et al 2000. The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta-arrestin-dependent scaffolding complex. Proc. Natl. Acad. Sci. USA 97: 11086-11091.
82. Kage, R., S.E. Leeman & N.D. Boyd 1993. Biochemical characterization of two different forms of the substance P receptor in rat submaxillary gland. J. Neurochem. 60: 347-351.
83. Mantyh, P.W. et al 1996. Differential expression of two isoforms of the neurokinin-1 (substance P) receptor in vivo. Brain Res. 719: 8-13.
84. Tuluc, F. et al 2009. Neurokinin 1 receptor isoforms and the control of innate immunity. Trends Immunol. 30: 271-276.
85. Chernova, I. et al 2009. Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R). J. Leukoc. Biol. 85: 154-164.
86. Tansky, M.F., C. Pothoulakis & S.E. Leeman 2007. Functional consequences of alteration of N-linked glycosylation sites on the neurokinin 1 receptor. Proc. Natl. Acad. Sci. USA 104: 10691-10696.
87. Beinborn, M. et al 2010. TGF-beta regulates T-cell neurokinin-1 receptor internalization and function. Proc. Natl. Acad. Sci. USA 107: 4293-4298.
88. Murphy, J.E. et al 2009. Endosomes: a legitimate platform for the signaling train. Proc. Natl. Acad. Sci. USA 106: 17615-17622.
89. Gillespie, E. et al 2010. Gene expression of the truncated neurokinin-1 receptor as well as two NF-kB subunits is altered in the transition of colonic epithelial cells from quiescent colitis to high grade dysplasia to carcinoma in colitis associated colorectal cancer. Presented at Digestive Disease Week, New Orleans, LA, May 1-6, 2010.
90. Palma, C. 2006. Tachykinins and their receptors in human malignancies. Curr. Drug Targets 7: 1043-1052.
91. Douglas, S.D. et al 2008. Neurokinin-1 receptor expression and function in human macrophages and brain: perspective on the role in HIV neuropathogenesis. Ann. N. Y. Acad. Sci. 1144: 90-96.
92. Evans, D.L. et al 1995. Stress-associated reductions of cytotoxic T lymphocytes and natural killer cells in asymptomatic HIV infection. Am. J. Psychiatry 152: 543-550.
93. Evans, D.L. et al 1997. Severe life stress as a predictor of early disease progression in HIV infection. Am. J. Psychiatry 154: 630-634.
94. Evans, D.L. et al 2002. Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am. J. Psychiatry 159: 1752-1759.
95. Elsawa, S.F. et al 2003. Reduced CTL response and increased viral burden in substance P receptor-deficient mice infected with murine gamma-herpesvirus 68. J. Immunol. 170: 2605-2612.
96. Johnson, T.R. & B.S. Graham 2004. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection. Pediatr. Infect. Dis. J. 23: S46-57.
97. Bost, K.L. 2004. Tachykinin-modulated anti-viral responses. Front. Biosci. 9: 1994-1998.
98. King, K.A. et al 2001. Exaggerated neurogenic inflammation and substance P receptor upregulation in RSV-infected weanling rats. Am. J. Respir. Cell. Mol. Biol. 24: 101-107.
99. Auais, A. et al 2003. Immunomodulatory effects of sensory nerves during respiratory syncytial virus infection in rats. Am. J. Physiol. Lung Cell. Mol. Physiol. 285: L105-113.
100. Zimmer, G. et al 2003. Virokinin, a bioactive peptide of the tachykinin family, is released from the fusion protein of bovine respiratory syncytial virus. J. Biol. Chem. 278: 46854-46861.
101. Robinson, P. et al 2009. Substance P is required for the pathogenesis of EMCV infection in mice. Int J. Clin. Exp. Med. 2: 76-86.
102. Chauhan, V.S. et al 2008. Neurogenic exacerbation of microglial and astrocyte responses to Neisseria meningitidis and Borrelia burgdorferi. J. Immunol. 180: 8241-8249.
103. Cooper, K.G., R. Zarnowski & J.P. Woods 2009. Histoplasma capsulatum encodes a dipeptidyl peptidase active against the mammalian immunoregulatory peptide, substance P. PLoS One 4: e5281.
104. Robinson, P. et al 2008. Substance P receptor antagonism for treatment of cryptosporidiosis in immunosuppressed mice. J. Parasitol. 94: 1150-1154.
105. Garza, A. et al 2010. Substance P signaling contributes to granuloma formation in Taenia crassiceps infection, a murine model of cysticercosis. J. Biomed. Biotechnol. 2010: 597086.
106. Reinke, E.K. et al 2006. Substance P receptor mediated maintenance of chronic inflammation in EAE. J. Neuroimmunol. 180: 117-125.
107. Weinstock, J.V. et al 1999. Immunoregulation within the granulomas of murine schistosomiasis mansoni. Microbes Infect. 1: 491-498.
108. Kramer, M.S. 2000. Update on substance P (NK-1 receptor) antagonists in clinical trials for depression. Neuropeptides 34: 255.
109. Kramer, M.S. et al 1998. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281: 1640-1645.
110. Kramer, M.S. et al 2004. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 29: 385-392.
111. Rupniak, N.M. 2002. New insights into the antidepressant actions of substance P (NK1 receptor) antagonists. Can. J. Physiol. Pharmacol. 80: 489-494.
112. Alvaro, G. & R. Di Fabio 2007. Neurokinin 1 receptor antagonists-current prospects. Curr. Opin. Drug Discov. Devel. 10: 613-621.
113. Hesketh, P.J. 2008. Chemotherapy-induced nausea and vomiting. N. Engl. J. Med. 358: 2482-2494.
114. Barden, N. et al 1983. Perturbation of rat brain serotonergic systems results in an inverse relation between substance P and serotonin concentrations measured in discrete nuclei. J. Neurochem. 41: 834-840.
115. Chan-Palay, V., G. Jonsson & S.L. Palay 1978. Serotonin and substance P coexist in neurons of the rat's central nervous system. Proc. Natl. Acad. Sci. USA 75: 1582-1586.
116. Hokfelt, T. et al 1978. Immunohistochemical evidence of substance P-like immunoreactivity in some 5-hydroxytryptamine-containing neurons in the rat central nervous system. Neuroscience 3: 517-538.
117. Jones, R.S. & H.R. Olpe 1984. Monoaminergic modulation of the sensitivity of neurones in the cingulate cortex to iontophoretically applied substance P. Brain Res. 311: 297-305.
118. Brodin, E. et al 1984. Chronic treatment with the serotonin uptake inhibitor zimelidine elevates substance P levels in rat spinal cord. Acta Physiol. Scand. 122: 209-211.
119. Brodin, E., S.O. Ogren & E. Theodorsson-Norheim 1987. Effects of subchronic treatment with imipramine, zimelidine and alaproclate on regional tissue levels of substance P- and neurokinin A/neurokinin B-like immunoreactivity in the brain and spinal cord of the rat. Neuropharmacology 26: 581-590.
120. Brodin, K. et al 1989. Increased levels of substance P and cholecystokinin in rat cerebral cortex following repeated electroconvulsive shock and subchronic treatment with a serotonin uptake inhibitor. Acta Physiol. Scand. 136: 613-614.
121. Giardina, G.A., S. Gagliardi & M. Martinelli 2003. Antagonists at the neurokinin receptors-recent patent literature. IDrugs 6: 758-772.
122. Swain, C.J. 1998. Neurokinin receptor antagonists. Prog. Med. Chem. 35: 57-81.
123. Takeda, Y. et al 1991. Molecular cloning, structural characterization and functional expression of the human substance P receptor. Biochem. Biophys. Res. Commun. 179: 1232-1240.
124. Hopkins, B. et al 1991. Isolation and characterisation of the human lung NK-1 receptor cDNA. Biochem. Biophys. Res. Commun. 180: 1110-1117.
125. Kris, R.M. et al 1991. Cloning and expression of the human substance K receptor and analysis of its role in mitogenesis. Cell Growth Differ. 2: 15-22.
126. Buell, G. et al 1992. Molecular characterization, expression and localisation of human neurokinin-3 receptor. FEBS Lett. 299: 90-95.
127. Huang, R.R. et al 1992. cDNA sequence and heterologous expression of the human neurokinin-3 receptor. Biochem. Biophys. Res. Commun. 184: 966-972.
128. Snider, R.M. et al 1991. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science. 251: 435-437.